Trial Profile
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Aug 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Busulfan; Gemcitabine; Melphalan; Rituximab; Vorinostat
- Indications Diffuse large B cell lymphoma; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 05 Aug 2023 Planned End Date changed from 1 Jul 2023 to 31 Jul 2024.
- 05 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 31 Jul 2024.
- 05 Aug 2023 Status changed from recruiting to active, no longer recruiting.